These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38043493)

  • 1. Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis.
    Chen C; Zhang B; Tu J; Peng Y; Zhou Y; Yang X; Yu Q; Tan X
    Eur J Med Chem; 2024 Jan; 264():115992. PubMed ID: 38043493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
    Zhang C; Liu Y; Wang Y; Ge X; Jiao T; Yin J; Wang K; Li C; Guo S; Xie X; Xie C; Nan F
    J Med Chem; 2022 Oct; 65(19):13452-13472. PubMed ID: 36107013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis.
    Mo C; Xu X; Zhang P; Peng Y; Zhao X; Chen S; Guo F; Xiong Y; Chu XJ; Xu X
    J Med Chem; 2023 Jul; 66(14):9363-9375. PubMed ID: 37424079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice.
    Jiang J; Ma Y; Liu Y; Lu D; Gao X; Krausz KW; Desai D; Amin SG; Patterson AD; Gonzalez FJ; Xie C
    Hepatol Commun; 2022 Dec; 6(12):3363-3378. PubMed ID: 36196594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hammerhead-type FXR agonists induce an enhancer RNA
    Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper J
    Elife; 2024 Apr; 13():. PubMed ID: 38619504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling.
    Pan L; Yu Z; Liang X; Yao J; Fu Y; He X; Ren X; Chen J; Li X; Lu M; Lan T
    Hepatol Commun; 2023 Feb; 7(2):e0039. PubMed ID: 36706173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
    Zhu Y; Zhang J; Min F; Yang X; Li L; Zhang Y; Hou X; Fang H
    Bioorg Med Chem Lett; 2022 Nov; 76():128993. PubMed ID: 36130662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
    Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
    J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
    Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
    J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist.
    Moon AN; Briand F; Breyner N; Song DK; Madsen MR; Kim H; Choi K; Lee Y; Namkung W
    Biomed Pharmacother; 2024 Apr; 173():116331. PubMed ID: 38428307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
    Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C
    Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
    Li H; Xi Y; Xin X; Tian H; Hu Y
    Biomed Pharmacother; 2020 Apr; 124():109915. PubMed ID: 31986416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.
    Gay MD; Cao H; Shivapurkar N; Dakshanamurthy S; Kallakury B; Tucker RD; Kwagyan J; Smith JP
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis.
    Hu YB; Liu XY; Zhan W
    Drug Des Devel Ther; 2018; 12():2213-2221. PubMed ID: 30038487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.
    Schumacher JD; Guo GL
    Handb Exp Pharmacol; 2019; 256():325-357. PubMed ID: 31201553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
    McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
    J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet.
    Kong B; Luyendyk JP; Tawfik O; Guo GL
    J Pharmacol Exp Ther; 2009 Jan; 328(1):116-22. PubMed ID: 18948497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.